Do analysts prefer VRAX or RBOT?

Virax Biolabs Group presently has a consensus target price of $25.00, indicating a potential upside of 1,415.15%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, research analysts plainly believe Virax Biolabs Group is more favorable than Vicarious Surgical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Vicarious Surgical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger valuation & earnings, VRAX or RBOT?

Virax Biolabs Group has higher revenue and earnings than Vicarious Surgical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $10K 132.00 -$5.02M N/A N/A Vicarious Surgical N/A N/A -$63.22M -$6.69 N/A

Is VRAX or RBOT more profitable?

Virax Biolabs Group's return on equity of 0.00% beat Vicarious Surgical's return on equity. Company Net Margins Return on Equity Return on Assets Virax Biolabs Group N/A N/A N/A Vicarious Surgical N/A -184.13% -112.50%

Do analysts recommend BBLG or RBOT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vicarious Surgical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better valuation & earnings, BBLG or RBOT?

Bone Biologics is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bone Biologics N/A N/A -$3.11M -$1.37 N/A Vicarious Surgical N/A N/A -$63.22M -$6.69 N/A

Is BBLG or RBOT more profitable?

Bone Biologics' return on equity of -57.87% beat Vicarious Surgical's return on equity. Company Net Margins Return on Equity Return on Assets Bone Biologics N/A -57.87% -53.65% Vicarious Surgical N/A -184.13% -112.50%

Do analysts rate RBOT or PFSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vicarious Surgical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, RBOT or PFSA?

Vicarious Surgical is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vicarious Surgical N/A N/A -$63.22M -$6.69 N/A Profusa N/A N/A -$35.82M -$5.62 thousand N/A

Is RBOT or PFSA more profitable?

Profusa's return on equity of 0.00% beat Vicarious Surgical's return on equity. Company Net Margins Return on Equity Return on Assets Vicarious Surgical N/A -184.13% -112.50% Profusa N/A N/A -1,731.09%

Do analysts rate BTCY or RBOT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Vicarious Surgical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts recommend RBOT or GCTK?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vicarious Surgical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, RBOT or GCTK?

Vicarious Surgical is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vicarious Surgical N/A N/A -$63.22M -$6.69 N/A GlucoTrack N/A N/A -$19.39M -$137.63 N/A

Is RBOT or GCTK more profitable?

Vicarious Surgical's return on equity of -184.13% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets Vicarious Surgical N/A -184.13% -112.50% GlucoTrack N/A -2,135.52% -290.22%

Vicarious Surgical (RBOT) Competitors

$0.05 +0.00 (+9.89%)

As of 10/14/2026 03:32 PM Eastern

Compare

RBOT vs. VRAX, BBLG, PFSA, BTCY, and GCTK

Should you buy Vicarious Surgical stock or one of its competitors? Vicarious Surgical's main competitors and comparable companies include Virax Biolabs Group (VRAX), Bone Biologics (BBLG), Profusa (PFSA), Biotricity (BTCY), and GlucoTrack (GCTK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Vicarious Surgical compare to Virax Biolabs Group?

Virax Biolabs Group (NASDAQ:VRAX) and Vicarious Surgical (NYSE:RBOT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 47.3% of Vicarious Surgical shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by insiders. Comparatively, 11.1% of Vicarious Surgical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Virax Biolabs Group's return on equity of 0.00% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Vicarious Surgical	N/A	-184.13%	-112.50%

Virax Biolabs Group has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Vicarious Surgical has a beta of 2.15, meaning that its stock price is 115% more volatile than the broader market.

Virax Biolabs Group presently has a consensus target price of $25.00, indicating a potential upside of 1,415.15%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, research analysts plainly believe Virax Biolabs Group is more favorable than Vicarious Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vicarious Surgical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Virax Biolabs Group has higher revenue and earnings than Vicarious Surgical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	132.00	-$5.02M	N/A	N/A
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A

In the previous week, Virax Biolabs Group had 4 more articles in the media than Vicarious Surgical. MarketBeat recorded 4 mentions for Virax Biolabs Group and 0 mentions for Vicarious Surgical. Virax Biolabs Group's average media sentiment score of 0.72 beat Vicarious Surgical's score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company	Overall Sentiment
Virax Biolabs Group	Positive
Vicarious Surgical	Neutral

Summary

Virax Biolabs Group beats Vicarious Surgical on 10 of the 12 factors compared between the two stocks.

How does Vicarious Surgical compare to Bone Biologics?

Bone Biologics (NASDAQ:BBLG) and Vicarious Surgical (NYSE:RBOT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

In the previous week, Bone Biologics had 1 more articles in the media than Vicarious Surgical. MarketBeat recorded 1 mentions for Bone Biologics and 0 mentions for Vicarious Surgical. Bone Biologics' average media sentiment score of 1.82 beat Vicarious Surgical's score of 0.00 indicating that Bone Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
Bone Biologics	Very Positive
Vicarious Surgical	Neutral

34.3% of Bone Biologics shares are held by institutional investors. Comparatively, 47.3% of Vicarious Surgical shares are held by institutional investors. 5.0% of Bone Biologics shares are held by insiders. Comparatively, 11.1% of Vicarious Surgical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Bone Biologics is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vicarious Surgical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Bone Biologics' return on equity of -57.87% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-57.87%	-53.65%
Vicarious Surgical	N/A	-184.13%	-112.50%

Bone Biologics has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Vicarious Surgical has a beta of 2.15, indicating that its share price is 115% more volatile than the broader market.

Summary

Bone Biologics beats Vicarious Surgical on 6 of the 10 factors compared between the two stocks.

How does Vicarious Surgical compare to Profusa?

Vicarious Surgical (NYSE:RBOT) and Profusa (NASDAQ:PFSA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profusa's return on equity of 0.00% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
Profusa	N/A	N/A	-1,731.09%

Vicarious Surgical is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A
Profusa	N/A	N/A	-$35.82M	-$5.62 thousand	N/A

47.3% of Vicarious Surgical shares are held by institutional investors. Comparatively, 9.8% of Profusa shares are held by institutional investors. 11.1% of Vicarious Surgical shares are held by insiders. Comparatively, 15.0% of Profusa shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Profusa had 2 more articles in the media than Vicarious Surgical. MarketBeat recorded 2 mentions for Profusa and 0 mentions for Vicarious Surgical. Profusa's average media sentiment score of 0.27 beat Vicarious Surgical's score of 0.00 indicating that Profusa is being referred to more favorably in the news media.

Company	Overall Sentiment
Vicarious Surgical	Neutral
Profusa	Neutral

Vicarious Surgical has a beta of 2.15, indicating that its stock price is 115% more volatile than the broader market. Comparatively, Profusa has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

Summary

Profusa beats Vicarious Surgical on 6 of the 11 factors compared between the two stocks.

How does Vicarious Surgical compare to Biotricity?

Biotricity (NASDAQ:BTCY) and Vicarious Surgical (NYSE:RBOT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, Biotricity's average media sentiment score of 0.00 equaled Vicarious Surgical'saverage media sentiment score.

Company	Overall Sentiment
Biotricity	Neutral
Vicarious Surgical	Neutral

Biotricity has higher revenue and earnings than Vicarious Surgical. Biotricity is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06M	0.08	-$14.09M	-$0.14	N/A
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 47.3% of Vicarious Surgical shares are owned by institutional investors. 1.6% of Biotricity shares are owned by insiders. Comparatively, 11.1% of Vicarious Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Vicarious Surgical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Vicarious Surgical has a net margin of 0.00% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
Vicarious Surgical	N/A	-184.13%	-112.50%

Biotricity has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market. Comparatively, Vicarious Surgical has a beta of 2.15, suggesting that its share price is 115% more volatile than the broader market.

Summary

Vicarious Surgical beats Biotricity on 7 of the 11 factors compared between the two stocks.

How does Vicarious Surgical compare to GlucoTrack?

Vicarious Surgical (NYSE:RBOT) and GlucoTrack (NASDAQ:GCTK) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

47.3% of Vicarious Surgical shares are held by institutional investors. Comparatively, 10.9% of GlucoTrack shares are held by institutional investors. 11.1% of Vicarious Surgical shares are held by insiders. Comparatively, 5.9% of GlucoTrack shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Vicarious Surgical's return on equity of -184.13% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
GlucoTrack	N/A	-2,135.52%	-290.22%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, GlucoTrack had 2 more articles in the media than Vicarious Surgical. MarketBeat recorded 2 mentions for GlucoTrack and 0 mentions for Vicarious Surgical. GlucoTrack's average media sentiment score of 1.79 beat Vicarious Surgical's score of 0.00 indicating that GlucoTrack is being referred to more favorably in the news media.

Company	Overall Sentiment
Vicarious Surgical	Neutral
GlucoTrack	Very Positive

Vicarious Surgical has a beta of 2.15, suggesting that its share price is 115% more volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Vicarious Surgical is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$137.63	N/A

Summary

Vicarious Surgical beats GlucoTrack on 7 of the 10 factors compared between the two stocks.

Get Vicarious Surgical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RBOT vs. The Competition

Export

Metric	Vicarious Surgical	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$356K	$5.59B	$7.19B	$23.07B
Dividend Yield	N/A	1.74%	2.52%	3.70%
P/E Ratio	-0.01	21.32	223.62	24.82
Price / Sales	N/A	65.09	547.34	21.35
Price / Cash	N/A	32.11	76.68	36.37
Price / Book	0.01	5.72	10.22	4.66
Net Income	-$63.22M	$146.93M	$3.50B	$1.07B
7 Day Performance	N/A	-1.61%	-3.50%	-1.40%
1 Month Performance	N/A	-4.38%	-7.78%	-3.92%
1 Year Performance	N/A	0.69%	0.79%	4.77%

Vicarious Surgical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RBOT Vicarious Surgical	N/A	$0.05 +9.9%	N/A	-99.2%	$356K	N/A	N/A	48	Gap Down
VRAX Virax Biolabs Group	2.7387 of 5 stars	$2.03 -15.4%	$25.00 +1,131.5%	-90.0%	$1.91M	$12.42K	N/A	26
BBLG Bone Biologics	1.0251 of 5 stars	$0.48 -1.2%	N/A	-83.9%	$1.34M	N/A	N/A	2	Gap Down
PFSA Profusa	0.3318 of 5 stars	$1.66 -5.1%	N/A	N/A	$1.06M	$100K	N/A	2	Gap Down
BTCY Biotricity	N/A	$0.05 -4.0%	N/A	-92.3%	$1.00M	$12.06M	N/A	46	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RBOT) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vicarious Surgical (RBOT) Competitors

RBOT vs. VRAX, BBLG, PFSA, BTCY, and GCTK

How does Vicarious Surgical compare to Virax Biolabs Group?

Summary

How does Vicarious Surgical compare to Bone Biologics?

Summary

How does Vicarious Surgical compare to Profusa?

Summary

How does Vicarious Surgical compare to Biotricity?

Summary

How does Vicarious Surgical compare to GlucoTrack?

Summary

Media Sentiment Over Time

RBOT vs. The Competition

Vicarious Surgical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vicarious Surgical (RBOT) Competitors

RBOT vs. VRAX, BBLG, PFSA, BTCY, and GCTK

How does Vicarious Surgical compare to Virax Biolabs Group?

Do insiders & institutionals believe in VRAX or RBOT?

Is VRAX or RBOT more profitable?

Which has more risk & volatility, VRAX or RBOT?

Do analysts prefer VRAX or RBOT?

Which has stronger valuation & earnings, VRAX or RBOT?

Does the media refer more to VRAX or RBOT?

Summary

How does Vicarious Surgical compare to Bone Biologics?

Does the media refer more to BBLG or RBOT?

Do insiders & institutionals believe in BBLG or RBOT?

Which has better valuation & earnings, BBLG or RBOT?

Do analysts recommend BBLG or RBOT?

Is BBLG or RBOT more profitable?

Which has more volatility & risk, BBLG or RBOT?

Summary

How does Vicarious Surgical compare to Profusa?

Is RBOT or PFSA more profitable?

Which has stronger valuation and earnings, RBOT or PFSA?

Do insiders and institutionals hold more shares of RBOT or PFSA?

Do analysts rate RBOT or PFSA?

Does the media prefer RBOT or PFSA?

Which has more volatility & risk, RBOT or PFSA?

Summary

How does Vicarious Surgical compare to Biotricity?

Does the media refer more to BTCY or RBOT?

Which has preferable valuation & earnings, BTCY or RBOT?

Do institutionals & insiders believe in BTCY or RBOT?

Do analysts rate BTCY or RBOT?

Is BTCY or RBOT more profitable?

Which has more risk and volatility, BTCY or RBOT?

Summary

How does Vicarious Surgical compare to GlucoTrack?

Do insiders & institutionals believe in RBOT or GCTK?

Is RBOT or GCTK more profitable?

Do analysts recommend RBOT or GCTK?

Does the media prefer RBOT or GCTK?

Which has more volatility & risk, RBOT or GCTK?

Which has better earnings & valuation, RBOT or GCTK?

Summary

Media Sentiment Over Time

RBOT vs. The Competition

Vicarious Surgical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools